


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sbpgroup.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

**TQH5528 “ORAL STAT6 DEGRADER” PRECLINICAL STUDY DATA
PRESENTED AT ERS 2026**

The Board of Directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that preclinical study data of TQH5528, an “oral STAT6 degrader” independently developed by the Group’s subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“**CTTQ**”), were presented as an oral presentation at the European Respiratory Society 2026 Annual Congress (ERS 2026), alongside an e-poster presentation.

TQH5528 is an oral STAT6 degrader developed by CTTQ based on its proprietary Orally Available Protein Degradator (OAPD[®]) platform. TQH5528 targets the IL-4/IL-13/STAT6 signalling axis and exerts its therapeutic effect through a protein degradation mechanism, with potential to become a new-generation therapeutic agent that offers a more convenient administration route as an alternative to injectable biologics.

Abstract title: Preclinical evaluation of TQH5528, an oral STAT6 degrader for Th2-driven allergic diseases

Abstract number: 5554

Presentation format: Oral presentation

Preclinical study data:

TQH5528 possesses a novel CRBN ligand structure and exhibits several key molecular characteristics: 1) No IMiD-related activity, thereby avoiding associated off-target risks; 2) potent STAT6 degradation activity at the picomolar level; 3) superior inhibitory efficacy against the IL-4/IL-13 pathway compared to KT-621; and 4) favourable oral exposure and bioavailability across multiple species, supporting development for oral administration.

Data from in vitro cellular assays indicate that, across multiple human Th2-related cell assessment systems, TQH5528 exhibits greater activity than KT-621 and dupilumab in terms of STAT6 protein degradation, pSTAT6 inhibition and suppression of downstream cytokine release, demonstrating distinct in vitro pharmacological advantages.

In vivo pharmacological and pharmacodynamic studies in non-human primates (NHPs) demonstrated that TQH5528 achieves rapid, profound and long-lasting degradation of the STAT6 protein. A single dose results in significant downregulation of STAT6; with multiple daily dosing, complete degradation of STAT6 in the blood is achieved within just 4 hours of administration; at low doses, >95% degradation of STAT6 is achieved in various tissues and cells, including the spleen, lungs and peripheral blood mononuclear cells (PBMCs), with the pharmacological effect exhibiting clear time- and dose-dependency.

In an HDM-induced asthma mouse model humanized for IL-4/IL-4R, TQH5528 demonstrated excellent in vivo therapeutic efficacy: it significantly improved methacholine-induced airway hyperresponsiveness, whilst simultaneously reducing inflammatory cells in peripheral blood and alleviating eosinophil infiltration, exhibiting outstanding in vivo efficacy.

As an oral STAT6 degrader, TQH5528 potently inhibits the IL-4/IL-13 pathway, achieving sustained STAT6 protein depletion without rebound in non-human primates; it demonstrates robust therapeutic efficacy in humanised asthma mouse model, and in vivo safety studies are currently underway.

Sources:

- [1] Preclinical evaluation of TQH5528, an oral STAT6 degrader for Th2-driven allergic diseases. Dan Mei, Baomin Liu, et al. ERS 2026 (#5554).
- [2] Potent and Selective Oral STAT6 Degradation, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks Th2 Inflammation in House Dust Mite Models of Asthma Prophylactically and Therapeutically. ATS Annual Meeting 2025 • May 16-21, 2025 • San Francisco, CA. Kymera Therapeutics.
- [3] Highly selective and reversible STAT6 inhibition demonstrates potential for differentiated efficacy and safety profile in type 2 allergic inflammation. Recludix Pharma Presented at the ATS 2025 International Conference, May 18 –21, 2025 in San Francisco, CA, USA.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 8 September 2026

As at the date of this announcement, the Board of the Company comprises five executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and Mr. Tse Hsin and six independent non-executive directors, namely Mr. Lu Zhengfei, Ms. Lu Hong, Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.